Catalent Inc - Company Profile
Powered by 
All the sales intelligence you need on Catalent Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Catalent Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Catalent Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Catalent Inc (Catalent), a subsidiary of Novo Holdings AS, provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The company offers complex, advanced formulation delivery technologies and related integrated solutions. It provides comprehensive pre-formulation, development, and both clinical and commercial scales for most traditional and advanced oral solid dose formats. Catalent also offers a wide range of injectable manufacturing solutions, including filling drugs or biologics into pre-filled syringes and glass-free vials, as well as formulation development and cell-line manufacturing. The company has manufacturing facilities in North America and Europe. Catalent is headquartered in Somerset, New Jersey, the US.
Headquarters
United States of America
Address
14 Schoolhouse Rd, Somerset, New Jersey, 08873-1213
Website
www.catalent.com
Telephone
1 732 5376200
No of Employees
16,900
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$4.4B
Catalent Inc premium industry data and analytics
Products and Services
| Services |
|---|
| Testing |
| Respiratory Products Formulation, Manufacturing, Micronization and Particle Engineering Services |
| Regulatory Consulting |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Asset Disposal | In August, the company sold its Nottingham, UK facility to Codis. |
| 2026 | Contracts/Agreements | In April, the company signed an agreement with Cartherics to use its cGMP‑compliant iPSC line to manufacture and commercialize Cartherics’ iPSC‑derived CAR‑NK cell therapies. |
| 2026 | Contracts/Agreements | In March, the company signed a partnership with GelMEDIX Inc to secure Catalent’s GMP-induced pluripotent stem cells (iPSC) and Catalent’s cell therapy manufacturing expertise and capabilities |
Competitor Comparison
| Key Parameters | Catalent Inc | ICON Plc | Charles River Laboratories International Inc | Parexel International Corp | Pharmaceutical Product Development LLC |
|---|---|---|---|---|---|
| Headquarters | United States of America | Ireland | United States of America | United States of America | United States of America |
| City | Somerset | Dublin | Wilmington | Raleigh | Wilmington |
| State/Province | New Jersey | Dublin | Massachusetts | North Carolina | North Carolina |
| No. of Employees | 16,900 | 40,200 | 18,300 | 24,000 | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John J. Greisch | Chairman | Executive Board | 2023 | 69 |
| Alessandro Maselli | Director; President; Chief Executive Officer | Executive Board | 2010 | 52 |
| Matti Masanovich | Chief Financial Officer; Senior Vice President | Senior Management | 2023 | 52 |
| Charles Lickfold | Chief Technology Officer; Senior Vice President | Senior Management | 2020 | 49 |
| Joseph A. Ferraro | General Counsel; Secretary; Senior Vice President; Chief Compliance Officer | Senior Management | 2023 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer